SEC Form 4 · accession 0001209191-16-126166
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith S Manchester
Director
Period of report
Jun 3, 2016
Accepted (ET)
Jun 7, 2016 · 1:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $3.99 | Jun 3, 2016 | A | 7,500 | A | — | Jun 2, 2026 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1The shares underlying this option fully vested on June 3, 2016.
- F2Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director of Roivant Sciences Ltd. on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP.